# Greece Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Greece HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Greece (GRC) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $1.6B - Products: 34 - Buyer markets: 27 - Average CAGR: +112.8% - Global sector size: $716.6B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $302.0B | $1.5B | $112.4B | +23.1% | 20 | +0.8% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $147.1B | $10.8M | $59.9B | +821.5% | 13 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $27.8B | $4.3M | $44.3B | +27.5% | 3 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $15.9B | $120.1 | $19.8B | -12.5% | 2 | +0.0% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $134.2K | $16.8B | +8.5% | 3 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $708.6K | $16.2B | -0.1% | 7 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $29.3B | $657.6K | $15.9B | +32.3% | 6 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $43.9M | $15.9B | +10.0% | 8 | +0.2% | | HS 300220 - Vaccines: for human medicine | $16.4B | $19.6M | $15.7B | +6.1% | 6 | +0.1% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $12.6B | $44.0M | $10.7B | +45.7% | 4 | +0.4% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $1.3M | $10.7B | +57.1% | 3 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $638.7K | $8.5B | +11.3% | 3 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $2.9M | $6.3B | +12.8% | 3 | +0.0% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $18.1M | $5.8B | +20.8% | 2 | +0.2% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $2.9B | $66.7 | $4.9B | -6.7% | 2 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $98.7 | $4.9B | -1.3% | 1 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $24.6K | $4.8B | +2.6% | 1 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $1.7M | $4.1B | +12.3% | 2 | +0.0% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $48.9K | $3.3B | -10.0% | 2 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $298.2K | $2.9B | +7.4% | 2 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $818.9K | $2.1B | +16.6% | 1 | +0.0% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $11.1K | $2.1B | -21.5% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.2M | $2.0B | +13.3% | 1 | +0.0% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $408.9 | $1.8B | +11.2% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $7.0K | $1.4B | +6.6% | 1 | +0.0% | | HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $11.2K | $1.4B | +5.0% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $865.4 | $1.4B | +14.8% | 1 | +0.0% | | HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $21.2K | $1.3B | -18.1% | 1 | +0.0% | | HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $10.4K | $1.3B | +6.6% | 1 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $1.3K | $1.2B | +30.4% | 1 | +0.0% | | HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $9.4K | $1.2B | +4.8% | 1 | +0.0% | | HS 281820 - Aluminium oxide: other than artificial corundum | $2.3B | $1.5M | $1.1B | -17.2% | 1 | +0.1% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $34.5 | $1.1B | -42.4% | 1 | +0.0% | | HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $85.3K | $1.1B | +45.6% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $116.3B calculated opportunity across 16 products. - Switzerland, Liechtenstein (CHE): $36.5B calculated opportunity across 4 products. - Germany (DEU): $35.8B calculated opportunity across 11 products. - Slovenia (SVN): $32.7B calculated opportunity across 4 products. - China (CHN): $24.0B calculated opportunity across 9 products. - Belgium (BEL): $23.9B calculated opportunity across 5 products. - Italy (ITA): $23.7B calculated opportunity across 4 products. - Netherlands (NLD): $20.7B calculated opportunity across 6 products. - Spain (ESP): $11.4B calculated opportunity across 6 products. - United Kingdom (GBR): $10.6B calculated opportunity across 5 products. - Mexico (MEX): $10.2B calculated opportunity across 5 products. - France (FRA): $10.1B calculated opportunity across 5 products. ## Growth stars - HS 300215: +821.5% average CAGR, $59.9B calculated opportunity. - HS 330210: +57.1% average CAGR, $10.7B calculated opportunity. - HS 382600: +45.7% average CAGR, $10.7B calculated opportunity. - HS 321590: +45.6% average CAGR, $1.1B calculated opportunity. - HS 300212: +32.3% average CAGR, $15.9B calculated opportunity. - HS 300390: +30.4% average CAGR, $1.2B calculated opportunity. - HS 293719: +27.5% average CAGR, $44.3B calculated opportunity. - HS 300490: +23.1% average CAGR, $112.4B calculated opportunity. - HS 330499: +20.8% average CAGR, $5.8B calculated opportunity. - HS 381512: +16.6% average CAGR, $2.1B calculated opportunity. ## Diversification opportunities - HS 300490: 20 buyer markets, $112.4B calculated opportunity. - HS 300215: 13 buyer markets, $59.9B calculated opportunity. - HS 300439: 8 buyer markets, $15.9B calculated opportunity. - HS 382499: 7 buyer markets, $16.2B calculated opportunity. - HS 300212: 6 buyer markets, $15.9B calculated opportunity. - HS 300220: 6 buyer markets, $15.7B calculated opportunity. - HS 382600: 4 buyer markets, $10.7B calculated opportunity. - HS 293719: 3 buyer markets, $44.3B calculated opportunity. - HS 293399: 3 buyer markets, $16.8B calculated opportunity. - HS 330210: 3 buyer markets, $10.7B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.